CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx, Inc. (CVRX) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (F). The rating has held at D+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | C- (2.0) | B (3.2) | F (0.5) | F (0.0) | D+ (1.7) |
| 2026-11-04 | B- (3.0) | C (2.2) | B (3.4) | F (0.4) | F (0.0) | D+ (1.8) |
| 2026-10-28 | B- (3.0) | C (2.2) | B (3.4) | F (0.6) | F (0.0) | D+ (1.8) |
| 2026-10-21 | B- (3.0) | C (2.2) | B (3.3) | F (0.6) | F (0.0) | D+ (1.8) |
| 2026-10-14 | B- (3.0) | C (2.2) | B (3.3) | F (0.6) | F (0.0) | D+ (1.8) |